Trials / Completed
CompletedNCT04648241
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TBE vaccine 0.5 mL | TBE vaccine 0.5 mL (intramuscular injection). |
| BIOLOGICAL | TBE vaccine 0.25 mL | TBE vaccine 0.25 mL (intramuscular injection). |
Timeline
- Start date
- 2021-01-18
- Primary completion
- 2022-02-21
- Completion
- 2022-02-21
- First posted
- 2020-12-01
- Last updated
- 2023-11-22
- Results posted
- 2023-11-22
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04648241. Inclusion in this directory is not an endorsement.